Results 51 to 60 of about 372,893 (296)

Two Cases of Chronic and Drug-Resistant Cutaneous Leishmaniasis as an Initial Presentation of the Underlying Lymphoproliferative Disorder

open access: yesمجله دانشکده پزشکی اصفهان, 2020
Background: Cutaneous leishmaniasis is an infectious disease caused by the protozoa of Leishmania genus, which cause serious public health issues in endemic regions across 80 countries.
Reza Mortezaei   +3 more
doaj   +1 more source

Synthesis, In Silico Studies, Antiprotozoal and Cytotoxic Activities of Quinoline‐Biphenyl Hybrids [PDF]

open access: yes, 2020
This is the pre-peer reviewed version of the following article: Synthesis, In Silico Studies, Antiprotozoal and Cytotoxic Activities of Quinoline‐Biphenyl Hybrids, which has been published in final form at https://doi.org/10.1002/slct.201903835.
Carda, Miguel   +6 more
core   +1 more source

Psychosocial burden of localised cutaneous Leishmaniasis: a scoping review

open access: yesBMC Public Health, 2018
BackgroundCutaneous Leishmaniasis (CL) is a parasitic skin disease, linked to poverty, and belonging to the group of Neglected Tropical Diseases. Depending on the severity, the type of lesions or scars, and the context, CL can lead to self- and social ...
Issam Bennis   +4 more
semanticscholar   +1 more source

Clinicoepidemiological Study of Cutaneous Leishmaniasis: A Hospital Based Study

open access: yesNepal Journal of Dermatology, Venereology & Leprology, 2023
Introduction: Cutaneous leishmaniasis is a tropical disease transmitted by the bite of an intracellular parasite infected sandfly. Visceral leishmaniasis is common in Nepal. However, cutaneous leishmaniasis remains rare with only limited number of cases
Sushmita Pradhan   +5 more
doaj   +3 more sources

Salvage therapy with Sodium chlorosum (formerly DAC N-055) for cases of refractory lupoid cutaneous leishmaniasis: results from a compassionate use study with 0.09% Sodium chlorosum in amphiphilic basic cream

open access: yesBMC Infectious Diseases, 2019
Background Lupoid cutaneous leishmaniasis (LCL) is known as a rare but serious complication of anthroponotic cutaneous leishmaniasis (ACL) resistant to conventional treatments.
Sara Molkara   +7 more
doaj   +1 more source

Human myiasis in Ecuador. [PDF]

open access: yes, 2020
We review epidemiological and clinical data on human myiasis from Ecuador, based on data from the Ministry of Public Health (MPH) and a review of the available literature for clinical cases.
Calvopina, M   +5 more
core   +1 more source

Cutaneous leishmaniasis in Pakistan

open access: yesDermatology Online Journal, 2005
Leishmaniasis is a major health problem worldwide. It is also a particular problem in the rural areas of Pakistan. The disease occurs in varying presentations, from the self-limited and even self-healing cutaneous forms to fatal systemic disease. Lesions of cutaneous leishmaniasis may occur anywhere on the body but the most likely sites are the exposed
Khan, Shiraz Jamal, Muneeb, Syed
openaire   +4 more sources

The Association of Serum Lipid Profiles and Dietary Intakes of Vitamin E and Fiber with Psoriasis Severity

open access: yesCaspian Journal of Internal Medicine, 2021
Background: Dyslipidemia has been reportedly associated with an increased risk of atherosclerosis among psoriatic patients. Dietary intake can be a key factor in the pathophysiology of psoriasis. Herein, we assessed serum lipid profile and dietary intake
Mohammad Javad Yazdanpanah   +5 more
doaj  

Visceral leishmaniasis patients display altered composition and maturity of neutrophils as well as impaired neutrophil effector functions [PDF]

open access: yes, 2016
Immunologically, active visceral leishmaniasis (VL) is characterised by profound immunosuppression, severe systemic inflammatory responses and an impaired capacity to control parasite replication.
Adem, E   +19 more
core   +3 more sources

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

open access: yesAdvanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy